Wire · opportunities
FDA Panel Recommends Compounding Approval for Wolverine Stack Peptides
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
The FDA's Pharmacy Compounding Advisory Committee voted narrowly to recommend adding six unapproved peptides, including BPC-157 and TB-500, to the list of ingredients allowed in compounded medications. The move aims to regulate black-market peptide sales through licensed pharmacies, but opponents warn it risks creating the false impression of FDA approval and could fuel marketing of unproven recovery and anti-ageing treatments.
This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Peptide wellness companies and telemedicine platforms are gaining a legal supply route through compounding pharmacies, but only if they don't claim FDA approval—which compounding clearance is not. The next six months will determine whether you can build a compliant retail model here, or whether the 'FDA-approved' marketing claim becomes your liability when regulators distinguish between what was approved to compound and what was proven to work.
◆ Related on Wire
◆ Topics